Moreover, an updated hypothetical model of AD biomarkers has suggested that vascular dysfunction, such as changes in the cerebral blood flow (CBF) and blood–brain barrier, may contribute to the initial stage of the pathophysiological process in AD, even before Aβ and tau pathology [4]. This evidence concerns the gene MAPT and Alzheimer disease.